Education
About Us
Working with TipRanks
Follow Us
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
XVIVO Stock Chart & Stats
kr176.00
-kr5.00(-1.20%)
At close: 4:00 PM EST
kr176.00
-kr5.00(-1.20%)
Day’s Range― - ―
52-Week Rangekr160.00 - kr519.00
Previous CloseN/A
Volume6.25K
Average Volume (3M)137.25K
Market Cap
kr6.28B
Enterprise Valuekr8.71B
Total Cash (Recent Filing)kr323.00M
Total Debt (Recent Filing)kr110.81M
Price to Earnings (P/E)210.1
Beta1.31
Next Earnings
Jan 27, 2026EPS Estimate
0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding31,499,470
10 Day Avg. Volume121,914
30 Day Avg. Volume137,251
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Xvivo Perfusion AB News
XVIVO FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.00 and its highest was kr519.00 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is kr6.28B.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Jan 27, 2026 which is in 86 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Oct 23, 2025. The company reported kr0.255 earnings per share for the quarter, missing the consensus estimate of kr0.436 by -kr0.181.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB does not currently pay dividends.
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.64.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of kr0.255 in its last earnings report, missing expectations of kr0.436. Following the earnings report the stock price went up 1.616%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in SE:XVIVO
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (XVIVO) is a Swedish medical technology company that specializes in organ preservation and perfusion solutions for transplantation. The company focuses on improving the viability of organs for transplant through innovative technologies and products, primarily targeting the fields of lung, kidney, and liver transplantation. XVIVO's core products include organ preservation solutions, perfusion devices, and associated services that enhance the effectiveness of transplant procedures and improve patient outcomes.
XVIVO Company Deck
XVIVO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in the Abdominal segment and strategic partnerships for service expansion in the U.S. However, challenges remain with slowed growth in the U.S. lung market and delays in regulatory approvals for heart and liver products.View all SE:XVIVO earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---